Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:LPCN
- CUSIP: N/A
- Web: www.lipocine.com
- Market Cap: $85.58 million
- Outstanding Shares: 20,581,000
- 50 Day Moving Avg: $4.12
- 200 Day Moving Avg: $4.05
- 52 Week Range: $3.03 - $5.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.29
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.22 per share
- Price / Book: 3.40
- EBIDTA: ($16,590,000.00)
- Return on Equity: -64.49%
- Return on Assets: -59.80%
- Current Ratio: 9.66%
- Quick Ratio: 9.66%
- Average Volume: 432,280 shs.
- Beta: 2.01
- Short Ratio: 6.01
Frequently Asked Questions for Lipocine (NASDAQ:LPCN)
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.01. View Lipocine's Earnings History.
When will Lipocine make its next earnings announcement?
Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?
3 analysts have issued 12 month price targets for Lipocine's stock. Their predictions range from $11.00 to $38.00. On average, they expect Lipocine's share price to reach $24.67 in the next twelve months. View Analyst Ratings for Lipocine.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include Fate Therapeutics (FATE), Vascular Biogenics (VBLT), Cempra (CEMP), Recro Pharma (REPH), Conatus Pharmaceuticals (CNAT), Summit Therapeutics PLC (SMMT), Trevena (TRVN), ProQR Therapeutics N.V. (PRQR), Redhill Biopharma (RDHL), Synthetic Biologics (SYN), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Cellular Biomedicine Group (CBMG), Dimension Therapeutics (DMTX), XBiotech (XBIT), Adverum Biotechnologies (ADVM), Sorrento Therapeutics (SRNE) and Agile Therapeutics (AGRX).
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Mahesh V. Patel Ph.D., Chairman of the Board, President, Chief Executive Officer
- Morgan R. Brown CPA, Chief Financial Officer, Executive Vice President
- Gregory Bass, Executive Vice President, Chief Commercial Officer
- Stephen Anthony Hill M.D., Lead Independent Director
- Jeffrey A. Fink, Director
- Richard Dana Ono, Director
- John W. Higuchi, Non-Executive Director
Who owns Lipocine stock?
Lipocine's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Royce & Associates LP (6.12%), Vanguard Group Inc. (2.83%), VHCP Management II LLC (2.01%), Dimensional Fund Advisors LP (1.26%), Ameriprise Financial Inc. (0.81%) and Federated Investors Inc. PA (0.46%). Company insiders that own Lipocine stock include John W Higuchi and Mahesh V Patel. View Institutional Ownership Trends for Lipocine.
Who sold Lipocine stock? Who is selling Lipocine stock?
Lipocine's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Bank of New York Mellon Corp, VHCP Management II LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Lipocine.
Who bought Lipocine stock? Who is buying Lipocine stock?
Lipocine's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Goldman Sachs Group Inc., LMR Partners LLP, Ameriprise Financial Inc. and Federated Investors Inc. PA. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi and Mahesh V Patel. View Insider Buying and Selling for Lipocine.
How do I buy Lipocine stock?
Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
MarketBeat Community Rating for Lipocine (NASDAQ LPCN)MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Lipocine stock can currently be purchased for approximately $4.15.
Consensus Ratings for Lipocine (NASDAQ:LPCN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$24.67 (494.38% upside)|
Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
(Data available from 9/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/10/2017||Roth Capital||Set Price Target||Buy||$38.00||Medium|
|8/7/2017||Canaccord Genuity||Set Price Target||Buy||$11.00||Low|
|4/26/2017||HC Wainwright||Reiterated Rating||Buy||$25.00||Low|
Earnings History for Lipocine (NASDAQ:LPCN)Earnings History by Quarter for Lipocine (NASDAQ LPCN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2017|| || || || || || || || |
Earnings Estimates for Lipocine (NASDAQ:LPCN)
2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($0.24)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lipocine (NASDAQ:LPCN)
Insider Ownership Percentage: 11.30%Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Institutional Ownership Percentage: 26.39%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/30/2015||John W Higuchi||Director||Buy||5,000||$12.68||$63,400.00|| |
|9/30/2015||Mahesh V. Patel||CEO||Buy||4,000||$11.84||$47,360.00|| |
|11/25/2014||Mahesh V Patel||CEO||Buy||2,000||$5.10||$10,200.00|| |
|11/24/2014||Mahesh V Patel||CEO||Buy||2,000||$5.45||$10,900.00|| |
|11/19/2014||Richard Dana Ono||Director||Buy||4,000||$5.14||$20,560.00|| |
|11/14/2014||Mahesh V Patel||CEO||Buy||2,000||$5.06||$10,120.00|| |
|11/13/2014||Mahesh V Patel||CEO||Buy||2,000||$5.05||$10,100.00|| |
|11/13/2014||Stephen A Hill||Director||Buy||4,000||$4.95||$19,800.00|| |
Headline Trends for Lipocine (NASDAQ:LPCN)
Latest Headlines for Lipocine (NASDAQ:LPCN)
|LPCN: Advisory Committee Required and USPTO Issues Motion for Tlando|
finance.yahoo.com - September 23 at 6:08 AM
|FDA Nod For ABMD, AERI Faces FDA Panel In Oct, IPCI Put On Notice, PFE Sues JNJ|
www.rttnews.com - September 22 at 11:06 AM
|Lipocine (LPCN) Announces FDA Advisory Committee Meeting for TLANDO - StreetInsider.com|
www.streetinsider.com - September 21 at 4:20 PM
|Lipocine Announces Motions Decision by USPTO in Interference Against Clarus - GlobeNewswire (press release)|
globenewswire.com - September 21 at 4:20 PM
|Lipocine Announces FDA Advisory Committee Meeting for TLANDO™|
finance.yahoo.com - September 21 at 4:20 PM
|Lipocine Announces Motions Decision by USPTO in Interference Against Clarus|
finance.yahoo.com - September 21 at 4:20 PM
|Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference|
finance.yahoo.com - September 20 at 2:51 AM
|Zacks: Analysts Anticipate Lipocine Inc. (LPCN) to Post -$0.31 Earnings Per Share|
www.americanbankingnews.com - September 15 at 10:10 PM
|Lipocine (LPCN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow|
seekingalpha.com - September 14 at 7:20 AM
|Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference|
finance.yahoo.com - September 5 at 4:13 PM
|Lipocine Inc. (LPCN) Expected to Post Earnings of -$0.31 Per Share|
www.americanbankingnews.com - August 28 at 10:28 AM
|Daily Technical Summary Reports on Generic Drugs Stocks -- Collegium Pharma, Momenta Pharma, Lipocine, and Diplomat Pharma|
www.bizjournals.com - August 24 at 8:49 AM
|Lipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date,|
www.nasdaq.com - August 15 at 1:09 AM
|Lipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018|
finance.yahoo.com - August 15 at 1:09 AM
|LPCN: Second Quarter Operational and Financial Results|
finance.yahoo.com - August 15 at 1:09 AM
|3 Things In Biotech You Should Learn Today: August 12, 2017|
seekingalpha.com - August 12 at 7:30 PM
|FY2017 Earnings Estimate for Lipocine Inc. Issued By Zacks Investment Research (NASDAQ:LPCN)|
www.americanbankingnews.com - August 10 at 10:42 AM
|Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism - Nasdaq|
www.nasdaq.com - August 10 at 3:07 AM
|Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism|
finance.yahoo.com - August 10 at 3:07 AM
|Lipocine Inc. (LPCN) Issues Earnings Results|
www.americanbankingnews.com - August 8 at 1:36 PM
|BRIEF-Lipocine posts Q2 loss per share $0.31|
www.reuters.com - August 7 at 8:54 PM
|Lipocine Inc. (LPCN) PT Set at $11.00 by Canaccord Genuity|
www.americanbankingnews.com - August 7 at 6:20 PM
|Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017 - GlobeNewswire (press release)|
globenewswire.com - August 7 at 3:52 PM
|Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017|
finance.yahoo.com - August 7 at 3:52 PM
|Lipocine reports 2Q loss|
finance.yahoo.com - August 7 at 3:52 PM
|Lipocine to Present at the Canaccord Genuity 37th Annual Growth Conference|
finance.yahoo.com - August 3 at 3:30 AM
|-$0.33 Earnings Per Share Expected for Lipocine Inc. (NASDAQ:LPCN) This Quarter|
www.americanbankingnews.com - July 20 at 8:20 PM
|BRIEF-Lipocine announces submission of special protocol assessment request to FDA on LPCN 1107, an oral alternative for prevention of preterm birth|
www.reuters.com - June 27 at 5:23 AM
|Lipocine (LPCN) Submission of Special Protocol Assessment on LPCN 1107 to FDA|
www.streetinsider.com - June 27 at 5:23 AM
|Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth - Nasdaq|
www.nasdaq.com - June 27 at 12:23 AM
|Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth|
finance.yahoo.com - June 27 at 12:22 AM
|Zacks: Brokerages Expect Lipocine Inc. (LPCN) Will Post Earnings of -$0.33 Per Share|
www.americanbankingnews.com - June 26 at 4:08 PM
|Licopine Pops And Drops After LPCN 1021 Meets Primary Endpoint - Benzinga|
www.benzinga.com - June 22 at 8:57 AM
|Lipocine Inc. (LPCN) PT Set at $38.00 by Roth Capital|
www.americanbankingnews.com - June 21 at 11:22 PM
|Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Lipocine and Portola Pharmaceuticals|
finance.yahoo.com - June 21 at 7:27 PM
|Lipocine Pops And Drops After LPCN 1021 Meets Primary Endpoint|
www.benzinga.com - June 20 at 7:18 PM
|Lipocine (LPCN) Announced Results from Dosing Validation and Dosing Flexibility Studies Evaluating Efficacy and Tolerability of LPCN 1021|
www.streetinsider.com - June 20 at 7:18 PM
|AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade|
www.rttnews.com - June 20 at 3:25 AM
|Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation|
www.nasdaq.com - June 19 at 10:24 PM
|After-Hours Stock Movers 06/19: (LPCN) (ENPH) (TSLA) Higher; (RS) (CMG) (CLVS) Lower (more...)|
www.streetinsider.com - June 19 at 10:24 PM
|BRIEF-Lipocine validates “no titration” dosing regimen with positive topline efficacy results for LPCN 1021|
www.reuters.com - June 19 at 10:24 PM
|Lipocine to Host Conference Call and Webcast to Discuss Top-Line ... - GlobeNewswire (press release)|
globenewswire.com - June 19 at 5:22 PM
|Lipocine Validates “No Titration” Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate|
finance.yahoo.com - June 19 at 5:22 PM
|The Future Of Lipocine's Lead Product Candidate, LPCN1021|
seekingalpha.com - June 8 at 7:19 PM
|Head-To-Head Survey: Kindred Biosciences (KIN) and Lipocine (LPCN)|
www.americanbankingnews.com - June 8 at 6:50 PM
|Lipocine to Present at the Jefferies 2017 Healthcare Conference - GlobeNewswire (press release)|
globenewswire.com - June 3 at 8:17 AM
|Lipocine to Present at the Jefferies 2017 Healthcare Conference|
finance.yahoo.com - June 2 at 7:44 PM
|-$0.33 Earnings Per Share Expected for Lipocine Inc (LPCN) This Quarter|
www.americanbankingnews.com - May 31 at 12:44 PM
|LPCN 1021 Readout in June; 1Q:17 R&D Costs Lower|
finance.yahoo.com - May 16 at 6:11 PM
|Lipocine Inc Expected to Earn FY2017 Earnings of ($1.17) Per Share (LPCN)|
www.americanbankingnews.com - May 15 at 8:43 AM
Lipocine (LPCN) Chart for Tuesday, September, 26, 2017